OPTIMI HEALTH CORP - OPTHF STOCK NEWS

Optimi Health Corp. (CSE: OPTI, OTCQB: OPTHF) announced its collaboration with Kydder Management Group Inc. to enhance its regulatory and corporate communications. Kydder Group will facilitate government relations, including leading a national coalition for psilocybin therapy access in Canada. CEO Bill Ciprick emphasized the importance of this partnership in aligning with regulatory standards and advancing the industry. Optimi aims to grow its presence in functional mushroom products and has facilities under construction in British Columbia.

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) has appointed Dr. Valerie H. Taylor as the principal investigator for a phase I psilocybin clinical dosing study at the University of Calgary. Dr. Taylor, a leading expert in mental health innovation and research, will oversee the trial under a partnership with IMPACT Clinical Trial Accelerator. This initiative aims to advance research on psilocybin's potential therapeutic benefits, with plans to submit a formal dosing study application to Health Canada in Q4. This development highlights Optimi's commitment to exploring innovative mental health solutions.

Optimi Health Corp. (OTCQB: OPTHF) announced a patent filing for a novel extraction method that significantly enhances the yield of Psilocybin and Psilocin from mushrooms. This breakthrough process addresses the historical instability of these alkaloids, which can lose up to three times their alkaloid content when dehydrated. The new technique not only improves extraction efficiency but also protects the compounds from degradation, potentially lowering production costs and enhancing bioavailability. Additionally, the method embraces green chemistry principles, aligning with Optimi's sustainability goals.

Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) has provided an update on its 20,000 sq. ft. production facility in Princeton, British Columbia. The project is currently three to four weeks behind schedule due to supply chain challenges, which the company considers acceptable in light of the global health crisis. The company is moving forward with construction for a Controlled Substance Dealers License and has been advised that the proposed security measures may meet Health Canada requirements. Progress on facility systems is ongoing, with most equipment expected on-site within a month.

Optimi Health Corp. announces the appointment of William J. Ciprick as CEO, effective September 7, 2021. With over 30 years of global experience in various industries, including leadership roles at BDC Advisory Services and Procter & Gamble, Ciprick aims to drive growth and commercialization of Optimi's functional mushroom products. He replaces Mike Stier, who will remain with the company as a director. Optimi focuses on the health and wellness sector and is nearing completion of a 20,000 square foot facility in Princeton, British Columbia.

Optimi Health Corp. announced preparations for a Q4 launch of online sales featuring a range of functional mushroom products, including capsules and a vegan protein formulation. Chief Marketing Officer Dane Stevens highlighted the company's goal of transforming into a revenue-generating entity, leveraging new revenues to spur value creation and fund ongoing initiatives. The initial sales will target the Canadian market with plans to enter the US market in 2022. Collaborations with marketing agencies aim to enhance consumer awareness and support the launch.

Optimi Health Corp. has engaged industry veteran John Simon to enhance its regulatory submissions and psychedelic research efforts. Simon brings extensive experience in regulatory affairs and has worked with FDA and Health Canada. His role is pivotal for Optimi's goal of conducting clinical trials on psilocybin-based formulations, meeting international standards, and securing intellectual property rights. The company aims to improve mental health through its innovative mushroom products and has received regulatory exemptions for research into psilocybin and psilocin.

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) has announced its inclusion in the first psychedelics Exchange Traded Fund (ETF), trading on the Neo Exchange since January 26, 2021. The ETF invests in companies involved in the psychedelics industry, with Optimi Health receiving a 1.74% weighting upon inclusion. Managed by Horizons ETF Management, the ETF aims to replicate the performance of the North American Psychedelics Index. CEO Mike Stier highlighted this inclusion as a significant milestone, enhancing visibility and investor confidence for Optimi's stakeholders.

Optimi Health Corp. has engaged Donohoe Advisory Associates LLC to assist in exploring strategies for a potential Nasdaq listing. Donohoe Advisory, founded by David A. Donohoe, Jr., consists of former Nasdaq staff and specializes in public company listings. CEO Mike Stier emphasized that this engagement marks significant progress towards achieving a senior market listing. Optimi is focused on developing a sophisticated mushroom brand, backed by research exemptions and licenses for Psilocybin and Psilocin, aiming for health and wellness markets.